Loading stock data…
$11.72-0.20 (-1.68%)
BrainsWay Ltd.
BrainsWay Ltd. in the Healthcare sector is trading at $11.72 with a market capitalization of $472M. Wall Street consensus targets $19.27 (3 analysts), implying a +64.4% move over the next 12 months. The stock is currently 33% below its 52-week high of $17.40, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.11M↑ | $15.53M↑ | $14.54M↑ | $13.51M↑ | $12.63M |
| Gross Profit | $12.77M↑ | $11.68M↑ | $11.12M↑ | $10.16M↑ | $9.50M |
| Operating Income | $2.39M↑ | $2.00M↑ | $1.92M↑ | $1.25M↑ | $578,000 |
| Net Income | $2.71M↑ | $2.29M↓ | $2.93M↑ | $1.57M↓ | $2.03M |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive...